Global Cutaneous Fibrosis Treatment Market by Type (Immunotherapy, Corticosteroids, AntFibrotic Drugs, Immunoglobulins, In 2018, Immunotherapy accounted for a major share of 49% the global Cutaneous Fibrosis Treatment market. And this product segment is poised to reach 340 million US$ by 2025 from 232.5 million US$ in 2018., Cutaneous Fibrosis Treatmen), By Application (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies) And By Region (North America, Latin America, Europe Asia Pacific and Middle East & Africa), Forecast From 2021 To 2030. The global cutaneous fibrosis treatment market is expected to grow at a CAGR of 5.71% during 2019-2025 and reach 385.25 million US$ in 2025 from 232.5 million US$ in 2018 with an estimated value of 340 million US$. The North American region is expected to dominate the global cutaneous fibrosis treatment market during the forecast period owing to high prevalence rates and increasing awareness among people about skin diseases such as psoriasis and eczema which are major causes for cutaneous fibrosis treatments in this region. The European region will also witness significant growth due to increasing awareness about skin diseases such as psoriasis which are major causes for cutaneous fibrosis treatments in this region.
- Increasing prevalence of chronic skin diseases such as psoriasis and eczema is driving the growth of the global Cutaneous Fibrosis Treatment market.
- Increasing awareness about skin diseases and their treatment options among people is also driving the growth of the global Cutaneous Fibrosis Treatment market.
- The increasing number of dermatologists in emerging economies such as China, India, Brazil, and Mexico is also driving the growth of the global Cutaneous Fibrosis Treatment market during this period (2018-2025) 4) Increasing number of dermatologists in emerging economies such as China, India, Brazil, and Mexico are also driving this growth during this period (2018-2025).
Industry Growth Insights published a new data on “Cutaneous Fibrosis Treatment Market”. The research report is titled “Cutaneous Fibrosis Treatment Market research by Types (Immunotherapy, Corticosteroids, Anti-Fibrotic Drugs, Immunoglobulins, In 2018, Immunotherapy accounted for a major share of 49% the global Cutaneous Fibrosis Treatment market. And this product segment is poised to reach 340 million US$ by 2025 from 232.5 million US$ in 2018., Cutaneous Fibrosis Treatmen), By Applications (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies, In Cutaneous Fibrosis Treatment market, the Hospitals Pharmacies holds an important share in terms of application, and it is expected to reach a revenue of 385.25 by 2025, at a CAGR of 5.71% during 2019 and 2025.), By Players/Companies AbbVie, Bayer, Merck, Bristol-Myers Squibb, Sanofi, Boehringer Ingelheim, Roche, GlaxoSmithKline, Pfizer, Novartis, LEO Pharma, Actelion, Cutaneous Fibrosis Treatmen”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Cutaneous Fibrosis Treatment Market Research Report
By Type
Immunotherapy, Corticosteroids, Anti-Fibrotic Drugs, Immunoglobulins, In 2018, Immunotherapy accounted for a major share of 49% the global Cutaneous Fibrosis Treatment market. And this product segment is poised to reach 340 million US$ by 2025 from 232.5 million US$ in 2018., Cutaneous Fibrosis Treatmen
By Application
Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies, In Cutaneous Fibrosis Treatment market, the Hospitals Pharmacies holds an important share in terms of application, and it is expected to reach a revenue of 385.25 by 2025, at a CAGR of 5.71% during 2019 and 2025.
By Companies
AbbVie, Bayer, Merck, Bristol-Myers Squibb, Sanofi, Boehringer Ingelheim, Roche, GlaxoSmithKline, Pfizer, Novartis, LEO Pharma, Actelion, Cutaneous Fibrosis Treatmen
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
237
Number of Tables & Figures
166
Customization Available
Yes, the report can be customized as per your need.
Global Cutaneous Fibrosis Treatment Market Report Segments:
The global Cutaneous Fibrosis Treatment market is segmented on the basis of:
Types
Immunotherapy, Corticosteroids, Anti-Fibrotic Drugs, Immunoglobulins, In 2018, Immunotherapy accounted for a major share of 49% the global Cutaneous Fibrosis Treatment market. And this product segment is poised to reach 340 million US$ by 2025 from 232.5 million US$ in 2018., Cutaneous Fibrosis Treatmen
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies, In Cutaneous Fibrosis Treatment market, the Hospitals Pharmacies holds an important share in terms of application, and it is expected to reach a revenue of 385.25 by 2025, at a CAGR of 5.71% during 2019 and 2025.
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- AbbVie
- Bayer
- Merck
- Bristol-Myers Squibb
- Sanofi
- Boehringer Ingelheim
- Roche
- GlaxoSmithKline
- Pfizer
- Novartis
- LEO Pharma
- Actelion
- Cutaneous Fibrosis Treatmen
Highlights of The Cutaneous Fibrosis Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Immunotherapy
- Corticosteroids
- Anti-Fibrotic Drugs
- Immunoglobulins
- In 2018, Immunotherapy accounted for a major share of 49% the global Cutaneous Fibrosis Treatment market. And this product segment is poised to reach 340 million US$ by 2025 from 232.5 million US$ in 2018.
- Cutaneous Fibrosis Treatmen
- By Application:
- Hospitals Pharmacies
- Retail Pharmacies
- Online Pharmacies
- In Cutaneous Fibrosis Treatment market, the Hospitals Pharmacies holds an important share in terms of application, and it is expected to reach a revenue of 385.25 by 2025, at a CAGR of 5.71% during 2019 and 2025.
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Cutaneous Fibrosis Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Cutaneous fibrosis is a skin condition that results in the development of thick, dry, fibrous tissue. Treatment typically involves various forms of therapy to reduce inflammation and promote healing.
Some of the key players operating in the cutaneous fibrosis treatment market are AbbVie, Bayer, Merck, Bristol-Myers Squibb, Sanofi, Boehringer Ingelheim, Roche, GlaxoSmithKline, Pfizer, Novartis, LEO Pharma, Actelion, Cutaneous Fibrosis Treatmen.
The cutaneous fibrosis treatment market is expected to grow at a compound annual growth rate of 5.71%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Cutaneous Fibrosis Treatment Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Cutaneous Fibrosis Treatment Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Cutaneous Fibrosis Treatment Market - Supply Chain
4.5. Global Cutaneous Fibrosis Treatment Market Forecast
4.5.1. Cutaneous Fibrosis Treatment Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Cutaneous Fibrosis Treatment Market Size (000 Units) and Y-o-Y Growth
4.5.3. Cutaneous Fibrosis Treatment Market Absolute $ Opportunity
5. Global Cutaneous Fibrosis Treatment Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Cutaneous Fibrosis Treatment Market Size and Volume Forecast by Type
5.3.1. Immunotherapy
5.3.2. Corticosteroids
5.3.3. Anti-Fibrotic Drugs
5.3.4. Immunoglobulins
5.3.5. In 2018, Immunotherapy accounted for a major share of 49% the global Cutaneous Fibrosis Treatment market. And this product segment is poised to reach 340 million US$ by 2025 from 232.5 million US$ in 2018.
5.3.6. Cutaneous Fibrosis Treatmen
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Cutaneous Fibrosis Treatment Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Cutaneous Fibrosis Treatment Market Size and Volume Forecast by Application
6.3.1. Hospitals Pharmacies
6.3.2. Retail Pharmacies
6.3.3. Online Pharmacies
6.3.4. In Cutaneous Fibrosis Treatment market, the Hospitals Pharmacies holds an important share in terms of application, and it is expected to reach a revenue of 385.25 by 2025, at a CAGR of 5.71% during 2019 and 2025.
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Cutaneous Fibrosis Treatment Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Cutaneous Fibrosis Treatment Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Cutaneous Fibrosis Treatment Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Cutaneous Fibrosis Treatment Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Cutaneous Fibrosis Treatment Demand Share Forecast, 2019-2026
9. North America Cutaneous Fibrosis Treatment Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Cutaneous Fibrosis Treatment Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Cutaneous Fibrosis Treatment Market Size and Volume Forecast by Application
9.4.1. Hospitals Pharmacies
9.4.2. Retail Pharmacies
9.4.3. Online Pharmacies
9.4.4. In Cutaneous Fibrosis Treatment market, the Hospitals Pharmacies holds an important share in terms of application, and it is expected to reach a revenue of 385.25 by 2025, at a CAGR of 5.71% during 2019 and 2025.
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Cutaneous Fibrosis Treatment Market Size and Volume Forecast by Type
9.7.1. Immunotherapy
9.7.2. Corticosteroids
9.7.3. Anti-Fibrotic Drugs
9.7.4. Immunoglobulins
9.7.5. In 2018, Immunotherapy accounted for a major share of 49% the global Cutaneous Fibrosis Treatment market. And this product segment is poised to reach 340 million US$ by 2025 from 232.5 million US$ in 2018.
9.7.6. Cutaneous Fibrosis Treatmen
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Cutaneous Fibrosis Treatment Demand Share Forecast, 2019-2026
10. Latin America Cutaneous Fibrosis Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Cutaneous Fibrosis Treatment Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Cutaneous Fibrosis Treatment Market Size and Volume Forecast by Application
10.4.1. Hospitals Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.4.4. In Cutaneous Fibrosis Treatment market, the Hospitals Pharmacies holds an important share in terms of application, and it is expected to reach a revenue of 385.25 by 2025, at a CAGR of 5.71% during 2019 and 2025.
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Cutaneous Fibrosis Treatment Market Size and Volume Forecast by Type
10.7.1. Immunotherapy
10.7.2. Corticosteroids
10.7.3. Anti-Fibrotic Drugs
10.7.4. Immunoglobulins
10.7.5. In 2018, Immunotherapy accounted for a major share of 49% the global Cutaneous Fibrosis Treatment market. And this product segment is poised to reach 340 million US$ by 2025 from 232.5 million US$ in 2018.
10.7.6. Cutaneous Fibrosis Treatmen
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Cutaneous Fibrosis Treatment Demand Share Forecast, 2019-2026
11. Europe Cutaneous Fibrosis Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Cutaneous Fibrosis Treatment Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Cutaneous Fibrosis Treatment Market Size and Volume Forecast by Application
11.4.1. Hospitals Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.4.4. In Cutaneous Fibrosis Treatment market, the Hospitals Pharmacies holds an important share in terms of application, and it is expected to reach a revenue of 385.25 by 2025, at a CAGR of 5.71% during 2019 and 2025.
11.5. Basis Point Share (BPS) Analysis y Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Cutaneous Fibrosis Treatment Market Size and Volume Forecast by Type
11.7.1. Immunotherapy
11.7.2. Corticosteroids
11.7.3. Anti-Fibrotic Drugs
11.7.4. Immunoglobulins
11.7.5. In 2018, Immunotherapy accounted for a major share of 49% the global Cutaneous Fibrosis Treatment market. And this product segment is poised to reach 340 million US$ by 2025 from 232.5 million US$ in 2018.
11.7.6. Cutaneous Fibrosis Treatmen
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Cutaneous Fibrosis Treatment Demand Share, 2019-2026
12. Asia Pacific Cutaneous Fibrosis Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Cutaneous Fibrosis Treatment Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Cutaneous Fibrosis Treatment Market Size and Volume Forecast by Application
12.4.1. Hospitals Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.4.4. In Cutaneous Fibrosis Treatment market, the Hospitals Pharmacies holds an important share in terms of application, and it is expected to reach a revenue of 385.25 by 2025, at a CAGR of 5.71% during 2019 and 2025.
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Cutaneous Fibrosis Treatment Market Size and Volume Forecast by Type
12.7.1. Immunotherapy
12.7.2. Corticosteroids
12.7.3. Anti-Fibrotic Drugs
12.7.4. Immunoglobulins
12.7.5. In 2018, Immunotherapy accounted for a major share of 49% the global Cutaneous Fibrosis Treatment market. And this product segment is poised to reach 340 million US$ by 2025 from 232.5 million US$ in 2018.
12.7.6. Cutaneous Fibrosis Treatmen
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Cutaneous Fibrosis Treatment Demand Share, 2019-2026
13. Middle East & Africa Cutaneous Fibrosis Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Cutaneous Fibrosis Treatment Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Cutaneous Fibrosis Treatment Market Size and Volume Forecast by Application
13.4.1. Hospitals Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.4.4. In Cutaneous Fibrosis Treatment market, the Hospitals Pharmacies holds an important share in terms of application, and it is expected to reach a revenue of 385.25 by 2025, at a CAGR of 5.71% during 2019 and 2025.
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Cutaneous Fibrosis Treatment Market Size and Volume Forecast by Type
13.7.1. Immunotherapy
13.7.2. Corticosteroids
13.7.3. Anti-Fibrotic Drugs
13.7.4. Immunoglobulins
13.7.5. In 2018, Immunotherapy accounted for a major share of 49% the global Cutaneous Fibrosis Treatment market. And this product segment is poised to reach 340 million US$ by 2025 from 232.5 million US$ in 2018.
13.7.6. Cutaneous Fibrosis Treatmen
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Cutaneous Fibrosis Treatment Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Cutaneous Fibrosis Treatment Market: Market Share Analysis
14.2. Cutaneous Fibrosis Treatment Distributors and Customers
14.3. Cutaneous Fibrosis Treatment Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. AbbVie
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Bayer
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Merck
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Bristol-Myers Squibb
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Sanofi
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Boehringer Ingelheim
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Roche
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. GlaxoSmithKline
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Pfizer
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Novartis
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. LEO Pharma
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Actelion
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
&n